Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

Healthcare advertisers and their marketing partners face challenges that other direct to consumer advertisers may not necessarily be confronted with. Namely, the ever-evolving world of privacy regulation and the requirements enacted by the federal and state governments with the goal of helping preserve patient anonymity.

Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge. In a new webinar, sponsored by PurpleLab, experts explore how PurpleLab’s data solutions can help foster a deeper understanding of physician prescribing behavior.

As the pharmaceutical and healthcare media industries face unprecedented change, the Preparing for 2025 roundtable convened leading experts to chart a path forward. Against a backdrop of rising patient expectations, accelerating technological advancements, and increasing regulatory pressures, this collaborative forum sought to address critical challenges while uncovering collective alignment for sustainable success.

We are in the middle of an ongoing data-driven revolution in the pharmaceutical industry. Data and analytics are reshaping how companies approach sales and marketing strategies – and customer experience.

Pharmaceutical advertisers and companies must develop marketing strategies that are multilayered as third-party cookies become a liability. Audience-based solutions remain part of this, but marketers should collaborate with their agency and ad tech partners to integrate real-world data in the pre-campaign planning, campaign launch and optimization phases. Discuss differences in content consumption based on health conditions, compare web behavior vs. TV viewing habits and how healthcare-focused supply analysis can feed into SPO applications.

With celebrity endorsements of drugs from GLP-1s to migraine medications, pharmaceutical advertisers are embracing high-profile celebrity marketing. But in the age of social media, you don’t have to be a celebrity to have influence.